Bristol Myers Squibb receives FDA approval for Reblozyl to treat anaemia
The expanded indication is based on interim results from the pivotal, open-label, randomised Phase III COMMANDS trial.
29 August 2023
29 August 2023
The expanded indication is based on interim results from the pivotal, open-label, randomised Phase III COMMANDS trial.
Abcam will operate as a standalone company within the Life Sciences segment of Danaher.
ImmunoGen will supply the product for development and commercial use in Japan.
Eubiologics will oversee the bulk manufacturing of the vaccine under the deal.
ST will be responsible for all marketing, regulatory and distribution activities relating to TW001 in Australia and New Zealand.
Sandoz strengthens its collection of anti-infective solutions through the acquisition of the key global echinocandin.
Data from the Phase III PAPILLON clinical trial, an open-label and randomised study, supported the sBLA.
The Centers for Medicare and Medicaid Services will soon release a list of 10 drugs that will be subject to drug price negotiations.
Outsourcing in Clinical Trials Southern California Conference 2023 will be returning to Hyatt Regency La Jolla at Aventine, USA on the 26th-27th September 2023! Focusing on interactive discussions to provide insight into the current major operational issues with running clinical trials in the coming years.
There are currently 13 authorized/approved COVID-19 vaccines in the 7 major pharma markets. Currently, vaccine developers plan to launch updated boosters prior to the upcoming 2023 fall season to target the latest dominant strain, Omicron XBB.1.5. Per GlobalData analysis, mRNA vaccines will likely continue to dominate the market, though as the pandemic winds down, the global COVID-19 vaccines market is expected to decline.
Give your business an edge with our leading industry insights.